Annals of Oncology Advance Access originally published online on November 9, 2005
Annals of Oncology 2006 17(2):259-261; doi:10.1093/annonc/mdj042
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Hypersensitivity reactions to oxaliplatin: experience in a single institute
Department of Clinical Oncology, Queen Mary Hospital, Pokfulam, Hong Kong
* Correspondence to: Dr S. W. K. Siu, Department of Clinical Oncology, 1/F Professorial Block, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong. Tel: +852-2855-4222; Fax: +852-2817-4503; E-mail: h9715590{at}graduate.hku.hk
Background: A rising incidence of hypersensitivity reactions to oxaliplatin has been observed as a result of increasing clinical use. Epidemiological and clinical features of these reactions are reviewed.
Patients and methods: Records of patients treated with a modified FOLFOX regimen from March 1999 to March 2004 were reviewed.
Results: One hundred and eighty patients were identified. Twenty-seven patients (15%) have been labelled as allergic to oxaliplatin, the proportion being higher among those receiving oxaliplatin in palliative second-line or above settings (19.6%) than in adjuvant or palliative first-line settings (10.2%). Some 2.2% of them developed grade 3–4 reactions. The reactions occurred after a mean (± SD) of 8.5 (± 4.2) cycles (range 1–18). Among the 14 patients re-exposed to oxaliplatin, four (28.6%) developed hypersensitivity reaction, in two of whom (14.3%) reactions were grade 3–4 in severity.
Conclusions: The risk of developing hypersensitivity reactions in patients receiving oxaliplatin should not be underestimated. The risk of developing potentially life-threatening hypersensitivity reactions should be explained to patients in the context of the potential benefits of such therapy. Patients receiving oxaliplatin infusion should be closely monitored. Once a patient develops hypersensitivity reaction to oxaliplatin, re-exposure should only be considered if the reaction is mild and there has been documented clinical benefit from previous doses of this agent.
Key words: chemotherapy, hypersensitivity, oxaliplatin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Ichikawa, A. Goto, S. Hirokawa, M. Kijima, T. Ishikawa, T. Chishima, H. Suwa, H. Yamamoto, S. Yamagishi, S. Osada, et al. Allergic Reactions to Oxaliplatin in a Single Institute in Japan Jpn. J. Clin. Oncol., June 25, 2009; (2009) hyp070v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Chung Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy Oncologist, June 1, 2008; 13(6): 725 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kitada, T. Dan, K. Takara, T. Tsuji, H. Yamasaki, T. Yokoyama, and M. Watari Oxaliplatin-induced hypersensitivity reaction displaying marked elevation of immunoglobulin E Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 233 - 235. [Abstract] [PDF]
|
|
|
|
|
|
N. Fuse, T. Doi, A. Ohtsu, S. Takeuchi, T. Kojima, K. Taku, M. Tahara, M. Muto, M. Asaka, and S. Yoshida Feasibility of Oxaliplatin and Infusional Fluorouracil/Leucovorin (FOLFOX4) for Japanese Patients with Unresectable Metastatic Colorectal Cancer Jpn. J. Clin. Oncol., June 1, 2007; 37(6): 434 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. de Vries, E. Mattijssen, and A. van Sorge Serious delayed hypersensitivity reaction to oxaliplatin Ann. Onc., November 1, 2006; 17(11): 1723 - 1724. [Full Text] [PDF]
|
|